October 30, 2025

Summarizing the Big Events in the Small Molecules Field

October 2025 highlights in the small molecules sector include developments in dermatitis treatment, improvements in epilepsy symptoms, and the effects of amoxicillin availability.

The Medicine Maker

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 27, 2025

State to End Vaccine Mandates — What Then?

After decades of required shots, Florida plans to make school immunizations optional — and experts stay quiet.

KFF Health News

October 22, 2025

FDA Redefining Depression Treatment with New Approvals?

Researchers analyze FDA-approved and Phase 3 antidepressants from 2009 to 2025.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 16, 2025

Depression Risk Rises Among Gabapentin Users

Gabapentin is most strongly associated with depression among women, lower-income patients, and those who sleep fewer than 7 hours per night.

Conexiant

October 13, 2025

First Alzheimer's Test for Primary Care

Roche’s FDA-cleared Elecsys pTau181 blood test helps physicians rule out Alzheimer’s pathology early and streamline diagnosis.

Conexiant

October 03, 2025

From Agent Orange to PCBs: Lessons for Care

Air Force reviews cancer risk in missile crews; early analyses show no excess mortality, but exposures to PCBs and benzene prompt vigilance and targeted histories.

KFF Health News

October 01, 2025

How Safe Are FDA-Cleared AI Tools?

“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."

Conexiant